NCT05458674
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentCriterium, Inc.
~17 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:TucatinibEribulinTrastuzumab
At a glance
Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the safety and tolerability of tucatinib in combination with eribulin and trastuzumab in patients with unresectable or recurrent metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, and trastuzumab deruxtecan.
Measured over 2 years
+1 more outcome measured
Conditions
Where it's being run
6 sites across 5 statesWashington2
Colorado1
District of Columbia1
New Mexico1
Wisconsin1
Study leadership
- Hank Kaplan, MD · PRINCIPAL_INVESTIGATOR · [email protected]
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- To assess the safety and tolerability of tucatinib in combination with eribulin and trastuzumab in patients with unresectable or recurrent metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, and trastuzumab deruxtecan.2 years
Incidence of adverse events and serious adverse events. Rate of grade 3 -4 toxicity, incidence of dose limiting toxicities, incidence of dose holding, dose reductions, and discontinuations of any and/or all of the three treatment agents. Incidence of cardiac and pulmonary complications.
- Evaluate the relative toxicity/tolerability of these therapeutic agents when used in combination in this patient cohort2 years
Rate of grade 3 -4 toxicity, incidence of dose limiting toxicities, incidence of dose holding, dose reductions, and discontinuations of any and/or all of the three treatment agents